Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo

被引:234
作者
Giuliani, N
Pedrazzoni, M
Negri, G
Passeri, G
Impicciatore, M
Girasole, G
机构
[1] Univ Parma, Ist Clin Med Gen & Terapia Med, I-43100 Parma, Italy
[2] Univ Parma, Ist Farm, I-43100 Parma, Italy
关键词
bisphosphonates; alendronate; etidronate; bone marrow; bone formation; fibroblast colony-forming units;
D O I
10.1016/S8756-3282(98)00033-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent in vitro findings suggest that bisphosphonates, potent inhibitors of osteoclastic bone resorption, may also have a direct action on osteoblasts. The purpose of this study was to search for potential effects of etidronate and alendronate on the formation of early and late osteoblastic cell precursors by measuring the number of colony-forming units for fibroblasts (CFU-F) and colony-forming units for osteoblasts (CFU-OB) in murine and human bone marrow cultures. In murine marrow cultures, etidronate (10(-5) to 10(-9) mol/L) significantly stimulated the formation of CFU-F with a maximal effect at 10(-5) mol/L (mean increase over control values +/- SD: 106 +/- 17%; p < 0.001), whereas alendronate had a biphasic effect, being stimulatory at concentrations below 10(-7) mol/L (78 +/- 5%; p < 0.001), and inhibitory at higher doses. The formation of CFU-OB was also inhibited hy both bisphosphonates at the highest concentrations (10(-5) mol/L and 10(-6) mol/L), but it was significantly stimulated at lower concentrations (from 10(-7) to 10(-9) mol/L for etidronate and 10(-7) to 10(-10) mol/L for alendronate; p < 0.001). In human bone marrow cultures, alendronate (10(-8) to 10(-12) mol/L) increased CFU-F formation with a maximal effect at 10(-10) mol/L (161 +/- 12%;p < 0.01). CFU-OB formation, observed only in the presence of dexamethasone (10(-8) mol/L), was markedly stimulated by alendronate at the above concentrations with a maximal increase at 10(-10) mol/L, (133 +/- 34%; p < 0.001). The in vivo short-term effects of bisphosphonates on the formation of early osteoblast precursors were also studied in bone marrow cultures from young female mice treated with weekly subcutaneous injections of etidronate (0.3, 3, and 30 mg/kg) or alendronate (0.3, 3, and 30 mu g/kg) and from aging female mice treated with the two lowest doses of both drugs. After 1 month of treatment, etidronate (0.3 and 3 mg/kg) and alendronate (0.3 and 3 mu g/kg) significantly increased the number of CFU-F colonies in the bone marrow from young and old animals, whereas the highest dose of both drugs had no effect in young mice. Our results, together with previously reported observations of bone-forming effects in osteoporosis, suggest that bisphosphonates may have, in vivo, a potentially relevant influence on cells of the osteoblastic lineage, distinct from their inhibitory action on osteoclasts. (C) 1998 by Elsevier Science Inc. All rights reserved.
引用
收藏
页码:455 / 461
页数:7
相关论文
共 37 条
  • [1] EFFECTS OF ORAL ALENDRONATE AND INTRANASAL SALMON-CALCITONIN ON BONE MASS AND BIOCHEMICAL MARKERS OF BONE TURNOVER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    ADAMI, S
    PASSERI, M
    ORTOLANI, S
    BROGGINI, M
    CARRATELLI, L
    CARUSO, I
    GANDOLINI, G
    GNESSI, L
    LAURENZI, M
    LOMBARDI, A
    NORBIATO, G
    PRYORTILLOTSON, S
    REDA, C
    ROMANINI, L
    SUBRIZI, D
    WEI, L
    YATES, AJ
    [J]. BONE, 1995, 17 (04) : 383 - 390
  • [2] MINERALIZATION DEFECTS WITH PAMIDRONATE THERAPY FOR PAGETS-DISEASE
    ADAMSON, BB
    GALLACHER, SJ
    BYARS, J
    RALSTON, SH
    BOYLE, IT
    BOYCE, BF
    [J]. LANCET, 1993, 342 (8885) : 1459 - 1460
  • [3] THE EFFECTS OF 2-YEAR TREATMENT WITH THE AMINOBISPHOSPHONATE ALENDRONATE ON BONE METABOLISM, BONE HISTOMORPHOMETRY, AND BONE STRENGTH IN OVARIECTOMIZED NONHUMAN-PRIMATES
    BALENA, R
    TOOLAN, BC
    SHEA, M
    MARKATOS, A
    MYERS, ER
    LEE, SC
    OPAS, EE
    SEEDOR, JG
    KLEIN, H
    FRANKENFIELD, D
    QUARTUCCIO, H
    FIORAVANTI, C
    CLAIR, J
    BROWN, E
    HAYES, WC
    RODAN, GA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) : 2577 - 2586
  • [4] BRUNNER G, 1993, BLOOD, V81, P631
  • [5] EFFECTS OF BASIC FIBROBLAST GROWTH-FACTOR ON BONE-FORMATION INVITRO
    CANALIS, E
    CENTRELLA, M
    MCCARTHY, T
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (05) : 1572 - 1577
  • [6] BISPHOSPHONATES DIRECTLY INHIBIT THE BONE-RESORPTION ACTIVITY OF ISOLATED AVIAN OSTEOCLASTS INVITRO
    CARANO, A
    TEITELBAUM, SL
    KONSEK, JD
    SCHLESINGER, PH
    BLAIR, HC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (02) : 456 - 461
  • [7] DIFFERENTIATION OF HUMAN BONE-MARROW OSTEOGENIC STROMAL CELLS IN VITRO - INDUCTION OF THE OSTEOBLAST PHENOTYPE BY DEXAMETHASONE
    CHENG, SL
    YANG, JW
    RIFAS, L
    ZHANG, SF
    AVIOLI, LV
    [J]. ENDOCRINOLOGY, 1994, 134 (01) : 277 - 286
  • [8] Endo N, 1996, J BONE MINER RES, V11, P535
  • [9] DIPHOSPHONATES INHIBIT HYDROXYAPATITE DISSOLUTION IN VITRO AND BONE RESORPTION IN TISSUE CULTURE AND IN VIVO
    FLEISCH, H
    RUSSELL, RGG
    FRANCIS, MD
    [J]. SCIENCE, 1969, 165 (3899) : 1262 - &
  • [10] EFFECTS OF ONE-YEAR CYCLICAL TREATMENT WITH CLODRONATE ON POSTMENOPAUSAL BONE LOSS
    GIANNINI, S
    DANGELO, A
    MALVASI, L
    CASTRIGNANO, R
    PATI, T
    TRONCA, R
    LIBERTO, L
    NOBILE, M
    CREPALDI, G
    [J]. BONE, 1993, 14 (02) : 137 - 141